GSE147240 dasatinib 0 v 2 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE147240_dasatinib_0_v_2_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE147240_dasatinib_0_v_2_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE147240_dasatinib_0_v_2_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE147240_dasatinib_0_v_2_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

small nucleolar RNA host gene 29

Gene

gametogenetin binding protein 2

Gene

double homeobox A pseudogene 8

Gene

long intergenic non-protein coding RNA 649

Gene

SVIL antisense RNA 1

Gene

KCNQ1 opposite strand/antisense transcript 1

Gene

zinc finger protein 892

Gene

UGDH antisense RNA 1

Gene

family with sequence similarity 225 member B

Gene

ribosomal protein L41 pseudogene 2

  • Gene

    small nucleolar RNA host gene 29


  • Gene

    gametogenetin binding protein 2


  • Gene

    double homeobox A pseudogene 8


  • Gene

    long intergenic non-protein coding RNA 649


  • Gene

    SVIL antisense RNA 1


  • Gene

    KCNQ1 opposite strand/antisense transcript 1


  • Gene

    zinc finger protein 892


  • Gene

    UGDH antisense RNA 1


  • Gene

    family with sequence similarity 225 member B


  • Gene

    ribosomal protein L41 pseudogene 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.